Tue, Jun 25, 10:02 AM (74 days ago)
Hepion Pharmaceuticals, Inc. filed an amendment to its Form 10-K for the fiscal year ending December 31, 2023. This amendment primarily updates Part III, Items 10-14, which were initially omitted in reliance on General Instruction G to Form 10-K and are now included directly rather than by reference to a proxy statement. Key changes include: - **Executive Changes**: John Cavan is now the Interim CEO and CFO following the departure of Dr. Robert Foster in December 2023. - **Board Composition**: New directors include John P. Brancaccio as Executive Chairman and Michael Purcell. - **Compensation**: Details on compensation for executives, including salaries and bonus structures, are provided. Notably, John Cavan's base salary is $400,000 with eligibility for a cash bonus up to 40% of his salary. - **Audit Fees**: Audit fees for 2023 were $426,703, up from $409,329 in 2022. - **Independence**: The Board consists of a majority of independent directors as per Nasdaq rules. No other changes were made to the original filing, and forward-looking statements remain in their historical context. This amendment also includes necessary certifications under the Sarbanes-Oxley Act.